JP2022532423A - 心血管系リスクを減らすためのゲノムに基づく方法 - Google Patents

心血管系リスクを減らすためのゲノムに基づく方法 Download PDF

Info

Publication number
JP2022532423A
JP2022532423A JP2021568564A JP2021568564A JP2022532423A JP 2022532423 A JP2022532423 A JP 2022532423A JP 2021568564 A JP2021568564 A JP 2021568564A JP 2021568564 A JP2021568564 A JP 2021568564A JP 2022532423 A JP2022532423 A JP 2022532423A
Authority
JP
Japan
Prior art keywords
prs
patient
risk
gene variants
cad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532423A5 (enExample
Inventor
ダマスク、エイミー
ポールディング、チャールズ
バラス、アリス
アベカシス、ゴンサロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022532423A publication Critical patent/JP2022532423A/ja
Publication of JP2022532423A5 publication Critical patent/JP2022532423A5/ja
Priority to JP2025229455A priority Critical patent/JP2026062658A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2021568564A 2019-05-17 2020-05-16 心血管系リスクを減らすためのゲノムに基づく方法 Pending JP2022532423A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025229455A JP2026062658A (ja) 2019-05-17 2025-12-04 心血管系リスクを減らすためのゲノムに基づく方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849670P 2019-05-17 2019-05-17
US62/849,670 2019-05-17
US201962933181P 2019-11-08 2019-11-08
US62/933,181 2019-11-08
PCT/US2020/033315 WO2020236670A1 (en) 2019-05-17 2020-05-16 Genome-based methods for reducing cardiovascular risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025229455A Division JP2026062658A (ja) 2019-05-17 2025-12-04 心血管系リスクを減らすためのゲノムに基づく方法

Publications (2)

Publication Number Publication Date
JP2022532423A true JP2022532423A (ja) 2022-07-14
JP2022532423A5 JP2022532423A5 (enExample) 2023-05-22

Family

ID=70978651

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568564A Pending JP2022532423A (ja) 2019-05-17 2020-05-16 心血管系リスクを減らすためのゲノムに基づく方法
JP2025229455A Pending JP2026062658A (ja) 2019-05-17 2025-12-04 心血管系リスクを減らすためのゲノムに基づく方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025229455A Pending JP2026062658A (ja) 2019-05-17 2025-12-04 心血管系リスクを減らすためのゲノムに基づく方法

Country Status (6)

Country Link
US (2) US12264366B2 (enExample)
EP (2) EP3969620B1 (enExample)
JP (2) JP2022532423A (enExample)
CA (1) CA3139943A1 (enExample)
MX (1) MX2021014015A (enExample)
WO (1) WO2020236670A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230057410A (ko) 2020-08-25 2023-04-28 리제너론 파마슈티칼스 인코포레이티드 Pcsk9 및 ldlr 조절인자를 사용한 패혈증 치료
CN119998446A (zh) 2022-06-07 2025-05-13 斯克里贝治疗公司 用于靶向pcsk9的组合物和方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526555A (ja) * 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
JP2011520098A (ja) * 2008-04-18 2011-07-14 クリティカル ケア ダイアグノスティクス インコーポレイテッド 主要有害心イベントのリスクを予測する方法
JP2015507205A (ja) * 2012-02-12 2015-03-05 ビージー メディシン，インコーポレイテッド 有害事象のリスク因子および予測
JP2015532715A (ja) * 2012-08-21 2015-11-12 クリティカル ケア ダイアグノスティクス インコーポレイテッド マルチマーカーリスク層別化
WO2018130670A1 (en) * 2017-01-12 2018-07-19 Cardioforecast Ltd Methods and kits for treating cardiovascular disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR091462A1 (es) 2012-06-15 2015-02-04 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US20190017119A1 (en) * 2017-07-12 2019-01-17 The General Hospital Corporation Genetic Risk Predictor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526555A (ja) * 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
JP2011520098A (ja) * 2008-04-18 2011-07-14 クリティカル ケア ダイアグノスティクス インコーポレイテッド 主要有害心イベントのリスクを予測する方法
JP2015507205A (ja) * 2012-02-12 2015-03-05 ビージー メディシン，インコーポレイテッド 有害事象のリスク因子および予測
JP2015532715A (ja) * 2012-08-21 2015-11-12 クリティカル ケア ダイアグノスティクス インコーポレイテッド マルチマーカーリスク層別化
WO2018130670A1 (en) * 2017-01-12 2018-07-19 Cardioforecast Ltd Methods and kits for treating cardiovascular disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOLDSTEIN, BENJAMIN A. ET AL., FRONTIERS IN GENETICS, vol. 5, no. 254, JPN6024022492, 1 August 2014 (2014-08-01), pages 1 - 9, ISSN: 0005496752 *
LANCET, vol. 385, JPN6025031713, 2015, pages 2264 - 71, ISSN: 0005841745 *

Also Published As

Publication number Publication date
US20210002724A1 (en) 2021-01-07
EP3969620A1 (en) 2022-03-23
EP4640848A3 (en) 2026-01-14
US12264366B2 (en) 2025-04-01
MX2021014015A (es) 2022-02-21
EP3969620B1 (en) 2025-06-25
JP2026062658A (ja) 2026-04-10
EP4640848A2 (en) 2025-10-29
US20250257406A1 (en) 2025-08-14
CA3139943A1 (en) 2020-11-26
WO2020236670A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
Castaldi et al. The association of genome-wide significant spirometric loci with chronic obstructive pulmonary disease susceptibility
JP2024028940A (ja) 核酸分子を分析するための方法およびシステム
US20250257406A1 (en) Genome-Based Methods For Reducing Cardiovascular Risk
Laganà et al. Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach
Sivapalaratnam et al. Monocyte gene expression signature of patients with early onset coronary artery disease
US20120052066A1 (en) Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
Khan et al. Advances and challenges for GWAS analysis in cardiac diseases: a focus on coronary artery disease (CAD)
Zhang et al. The chromatin remodeling factor Arid1a cooperates with Jun/Fos to promote osteoclastogenesis by epigenetically upregulating Siglec15 expression
Al-Baldawi et al. Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia
JP2023519600A (ja) 線維性状態の治療におけるバイオマーカーの使用
D’Onofrio et al. Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat
US20020164598A1 (en) Method for evaluating and applying an individual's genetic characteristics to determine response to cardiovascular medication therapy
JP7018544B2 (ja) 心房細動の処置のためのブシンドロールを伴う方法および組成物
HK40130500A (en) Genome-based methods for reducing cardiovascular risk
Watson et al. Use of oncogene overlap by tissue-based next-generation sequencing to explore the mutational landscape and survival impact of HER2, KRAS and MET copy-number gain in nonsmall cell lung cancer
JP5601685B2 (ja) Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する
Mishra et al. Gene set analysis of transcriptomics data identifies new biological processes associated with early markers of atherosclerosis but not with those of osteoporosis: Atherosclerosis-osteoporosis co/multimorbidity study in the Young Finns Study
Ichimura et al. Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy
SCALLOP consortium et al. Mapping pQTLs of circulating inflammatory proteins identifies drivers of immune-related disease risk and novel therapeutic targets
JP2010528262A5 (enExample)
US20240301499A1 (en) Method for identifying hard-to-treat osteosarcoma patients at diagnosis and improving their outcome by providing new therapy
EP0939136A1 (en) Assay for predicting the angiographic response to lipid-lowering therapy in patients
Mangas Rojas et al. A microRNA Signature for the Diagnosis of Statins Intolerance
Lee et al. Whole exome precision oncology targeting synthetic lethal vulnerabilities across the tumor transcriptome
Eken et al. POS0675 DIFFERENCES IN THE CHARACTERISTICS OF D2T/NOND2T-RA PATIENTS AND FACTORS ASSOCIATED WITH D2T-RA AT B/TSDMARD START

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251204